<code id='4E196D6D86'></code><style id='4E196D6D86'></style>
    • <acronym id='4E196D6D86'></acronym>
      <center id='4E196D6D86'><center id='4E196D6D86'><tfoot id='4E196D6D86'></tfoot></center><abbr id='4E196D6D86'><dir id='4E196D6D86'><tfoot id='4E196D6D86'></tfoot><noframes id='4E196D6D86'>

    • <optgroup id='4E196D6D86'><strike id='4E196D6D86'><sup id='4E196D6D86'></sup></strike><code id='4E196D6D86'></code></optgroup>
        1. <b id='4E196D6D86'><label id='4E196D6D86'><select id='4E196D6D86'><dt id='4E196D6D86'><span id='4E196D6D86'></span></dt></select></label></b><u id='4E196D6D86'></u>
          <i id='4E196D6D86'><strike id='4E196D6D86'><tt id='4E196D6D86'><pre id='4E196D6D86'></pre></tt></strike></i>

          fashion

          fashion

          author:knowledge    Page View:16
          Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

          Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

          The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

          advertisement

          But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Former Pear Therapeutics executives start new VC firm
          Former Pear Therapeutics executives start new VC firm

          SerialbiotechentrepreneurBobLangerwillserveasanadvisertoT.rxCapital.PatGreenhouse/GlobeStaffExecutiv

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          How the drug

          MollyFergusonforSTATAmericanmedicineisatragicparadox.Anexample:Cancerpatientsarelikelydyingasaresult